keyword
MENU ▼
Read by QxMD icon Read
search

Vaginal atrophy

keyword
https://www.readbyqxmd.com/read/28523261/rejuvenation-using-platelet-rich-plasma-and-lipofilling-for-vaginal-atrophy-and-lichen-sclerosus
#1
Seok Hwan Kim, Eun Soo Park, Tae Hee Kim
Vaginal atrophy is a common condition among peri- and post-menopausal women. Symptoms of vaginal dryness, pruritus, irritation, loss of subcutaneous fat, sparse pubic hair and dyspareunia occur due to decreased estrogen level. Estrogen-based treatments are effective. But many patients are reluctant to be treated due to health concerns. As alternatives, we explored the efficacy of platelet-rich plasma (PRP) and lipofilling. A 67-year-old female patient with vaginal atrophy was referred to our department. Treatment using estrogen cream had failed to improve patient's symptoms...
April 2017: Journal of Menopausal Medicine
https://www.readbyqxmd.com/read/28503946/fractional-co2-laser-therapy-a-new-challenge-for-vulvovaginal-atrophy-in-postmenopausal-women
#2
G P Siliquini, V Tuninetti, V E Bounous, F Bert, N Biglia
OBJECTIVE: To evaluate the effects of CO2 laser in the treatment of vulvovaginal atrophy (VVA) in postmenopausal women. METHODS: VVA was assessed in 87 postmenopausal women (mean age 58.6 ± 6.9 years) before and after the treatment. The protocol consisted of three monthly treatments and included the treatment of vulva. Subjective measures included VAS (Visual Analog Scale) both for vaginal dryness and dyspareunia; DIVA (Day-by-day Impact of Vaginal Aging); a questionnaire on treatment satisfaction and one about the degree of pain during the procedure...
May 15, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28492016/vaginal-rejuvenation-using-energy-based-devices
#3
REVIEW
Cheryl Karcher, Neil Sadick
Physiologic changes in a woman's life, such as childbirth, weight fluctuations, and hormonal changes due to aging and menopause, may alter the laxity of the vaginal canal, damage the pelvic floor, and devitalize the mucosal tone of the vaginal wall. These events often lead to the development of genitourinary conditions such as stress urinary incontinence; vaginal atrophy; dryness; and physiologic distress affecting a woman's quality of life, self-confidence, and sexuality. Various treatment modalities are currently available to manage these indications, varying from invasive vaginal surgery to more benign treatments like topical vaginal hormonal gels or hormone-replacement therapy...
September 2016: International Journal of Women's Dermatology
https://www.readbyqxmd.com/read/28490209/retrospective-analysis-in-46-women-with-vulvovaginal-atrophy-treated-with-ospemifene-for-12-weeks-improvement-in-overactive-bladder-symptoms
#4
Michele Carlo Schiavi, Marzio Angelo Zullo, Pierangelo Faiano, Ottavia D'Oria, Giovanni Prata, Vanessa Colagiovanni, Andrea Giannini, Chiara Di Tucci, Giorgia Perniola, Violante Di Donato, Marco Monti, Ludovico Muzii, Pierluigi Benedetti Panici
AIMS: The aim of this study was to assess the effectiveness and safety of ospemifene in the improvement of overactive bladder (OAB) symptoms in postmenopausal women affected by vulvovaginal atrophy (VVA). METHODS: Forty-six postmenopausal patients affected by VVA with OAB syndrome were enrolled for the study. All patients received Ospemifene 60 mg for 12 weeks. Clinical examination, 3-day voiding diary, urodynamic testing, ultrasound measurement of endometrial and bladder wall thickness (BWT) and the Vaginal Health Index (VHI) were performed at baseline and 12 weeks...
May 11, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28440666/relationship-between-delivery-modes-and-genitourinary-syndrome-among-postmenopausal-women
#5
M Yaralizadeh, P Abedi, P Salehinejad
OBJECTIVES: Many postmenopausal women suffer from genitourinary syndrome of menopause (GSM) due to the lack of estrogen. This study aimed to evaluate the relationship between mode of delivery and GSM among postmenopausal women. METHODS: We performed a case-control study of women who had had either vaginal delivery or Cesarean section. Data were collected through a sociodemographic questionnaire and a check list for assessing signs and symptoms of GSM. Subjective symptoms of vaginal atrophy (dryness, dyspareunia, itching, burning and paleness), pH of the vagina and maturation index were assessed and recorded...
April 25, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28419068/visual-improvements-in-vaginal-mucosa-correlate-with-symptoms-of-vva-data-from-a-double-blind-placebo-controlled-trial
#6
James A Simon, David F Archer, Risa Kagan, Brian Bernick, Shelli Graham, Ginger D Constantine, Sebastian Mirkin
OBJECTIVE: To evaluate the response of the vaginal mucosa with TX-004HR and its correlation with vulvar and vaginal atrophy (VVA) symptoms, and whether visual examination is a useful measure for assessing VVA. METHODS: REJOICE was a 12-week, phase 3, multicenter, randomized, double-blind, placebo-controlled study of a vaginal, muco-adhesive, 17β-estradiol softgel capsule (TX-004HR 4, 10, and 25 μg) in postmenopausal women with VVA and moderate-to-severe dyspareunia...
April 17, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28398023/clinical-profile-of-women-with-vva-who-are-not-candidates-for-local-vaginal-oestrogen-therapy
#7
Rossella E Nappi, Filippo Murina, Giuseppina Perrone, Paola Villa, Nicoletta Biglia
Vulvar and vaginal atrophy (VVA) is a chronic medical condition in postmenopausal women, which is predominantly due to a permanent cessation of ovarian oestrogen production. Current available treatment options for VVA are over-the-counter (OTC) symptomatic relief products or local oestrogen therapy (LET) aiming to treat this underlying atrophic condition. Recent surveys indicated that these products decrease sexual spontaneity, are messy and indiscrete. Ospemifene is an oral daily drug, which has proven to treat vaginal dryness and dyspareunia effectively...
April 10, 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28391746/management-of-vaginal-atrophy-a-real-mess-results-from-the-agata-study
#8
Federica Palma, Anjeza Xholli, Angelo Cagnacci
OBJECTIVES: To investigate the management of vaginal atrophy (VA) in a population-based study. STUDY DESIGN: A sub-study of a cross-sectional multicenter study on 913 postmenopausal women. MAIN OUTCOME MEASURES: Management of VA was investigated on the 274 women referring having received a previous diagnosis of VA. RESULTS: Women had received, no therapy (9.8%), systemic hormones (9.2%), intra-vaginal estrogens (44.5%) or local non-hormonal (36...
April 8, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28381099/oxytocin-stimulates-cell-proliferation-in-vaginal-cell-line-vk2e6e7
#9
Theodora K Kallak, Kerstin Uvnäs-Moberg
Objective During and after menopause, the symptoms of vaginal atrophy cause great discomfort and necessitate effective treatment options. Currently, vaginally applied oxytocin is being investigated as a treatment for the symptoms of vaginal atrophy in postmenopausal women. To clarify the mechanisms behind oxytocins effects on vaginal atrophy, the present study investigated the effects of oxytocin on cell proliferation in the cells of the Vk2E6E7 line, a non-tumour vaginal cell line. The study also compared the effects of oxytocin with those of estradiol (E2)...
March 2017: Post Reproductive Health
https://www.readbyqxmd.com/read/28364869/a-vaginal-estradiol-softgel-capsule-tx-004hr-has-negligible-to-very-low-systemic-absorption-of-estradiol-efficacy-and-pharmacokinetic-data-review
#10
REVIEW
James A Simon, David F Archer, Ginger D Constantine, James H Pickar, Julia M Amadio, Brian Bernick, Shelli Graham, Sebastian Mirkin
This paper reviews the efficacy, safety, and systemic absorption of estradiol with TX-004HR, an investigational, low-dose 17β-estradiol vaginal softgel capsule, designed to treat vulvar and vaginal atrophy (VVA) in postmenopausal women, with an improved user experience. In phase 2 (NCT02449902) and phase 3 REJOICE (NCT02253173) studies, TX-004HR significantly improved the proportions of vaginal superficial and parabasal cells and vaginal pH, and in the phase 3 study decreased the severity of dyspareunia, vaginal dryness, and vulvar and/or vaginal itching or irritation...
May 2017: Maturitas
https://www.readbyqxmd.com/read/28355090/consistency-of-effect-with-a-low-dose-estradiol-vaginal-capsule-tx-004hr-evaluating-improvement-in-vaginal-physiology-and-moderate-to-severe-dyspareunia-in-subgroups-of-postmenopausal-women
#11
Ginger D Constantine, Celine Bouchard, James H Pickar, David F Archer, Shelli Graham, Brian Bernick, Sebastian Mirkin
BACKGROUND: The 12-week, randomized, double-blind, placebo-controlled, multicenter, phase 3 REJOICE trial demonstrated that TX-004HR, an investigational, applicator-free, low-dose vaginal softgel capsule containing solubilized 17β-estradiol, effectively and rapidly treats symptoms of vulvar and vaginal atrophy (VVA) with negligible to very low systemic absorption. The aim of this analysis was to assess whether the efficacy of TX-004HR varies with age, body mass index (BMI), uterine status, pregnancy status, and vaginal delivery...
March 29, 2017: Journal of Women's Health
https://www.readbyqxmd.com/read/28323747/supporting-a-youth-with-cerebellar-ataxia-into-adolescence
#12
Veronica Meneses, Zurisadai Gonzalez-Castillo, Veronica B Edgar, Marilyn Augustyn
Zoe, a 13-year-old white girl, presents as a new patient to your pediatric clinic with complaints of frequent emesis, anxiety, and learning problems, and previous diagnosis of cerebellar ataxia. Parents accompany Zoe and state, "it is really hard for her to go out, she gets sick and falls easily." She was born full term by vaginal delivery without complications. Given globally delayed milestones, she received early intervention services. Feeding problems began at infancy, including gastroesophageal reflux and aspiration pneumonia...
April 2017: Journal of Developmental and Behavioral Pediatrics: JDBP
https://www.readbyqxmd.com/read/28323042/comparison-of-intravaginal-0-5-prasterone-0-3mg-conjugated-estrogens-and-10%C3%AE-g-estradiol-on-estrogen-related-symptoms-of-vulvovaginal-atrophy
#13
REVIEW
David F Archer, Fernand Labrie, Marlene Montesino, Céline Martel
The objective is to compare the effect of intravaginal dehydroepiandrosterone (DHEA, prasterone), conjugated equine estrogens (CEE) and estradiol (E2) on moderate to severe dyspareunia and/or vaginal dryness. In a review of available data, independent prospective, randomized, double-blind and placebo-controlled Phase III 12-week clinical trials involved daily administration of 6.5mg (0.50%) prasterone, daily (21days on/7days off) 0.3mg CEE, twice weekly 0.3mg CEE or 10 μg E2 daily for 2 weeks followed by twice weekly for 10 weeks...
March 17, 2017: Journal of Steroid Biochemistry and Molecular Biology
https://www.readbyqxmd.com/read/28277141/local-hormone-therapy-for-genitourinary-syndrome-of-menopause-in-breast-cancer-patients-is-it-safe
#14
María Fernanda Garrido Oyarzún, Camil Castelo-Branco
The genitourinary syndrome of menopause (GSM) is a frequent complaint among breast cancer (BC) survivors that lead to an important affection of their quality of life (QoL). Lifestyle measures such as smoking cessation or regular sexual activity are usually insufficient to significantly improve GMS and although therapies such as lubricants and polycarbophil moisturized gels are considered first-line therapies to alleviate symptoms of vulvovaginal atrophy, these non-hormonal options are not able to reverse atrophy once it occurs...
February 21, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28277131/macro-regional-variation-in-attitudes-toward-and-experiences-of-vulvar-and-vaginal-atrophy-among-italian-post-menopausal-women-a-post-hoc-analysis-of-revive-survey-data
#15
Rossella E Nappi, Martire Particco, Nicoletta Biglia, Angelo Cagnacci, Costantino Di Carlo, Stefano Luisi, Anna Maria Paoletti
Italian participants in the European REVIVE survey reported that vaginal and vulvar atrophy (VVA) impaired various aspects of their lives, notably the ability to enjoy sex. The aim of the present study was to explore regional differences in knowledge, experiences, and treatment of VVA in the Italian REVIVE sample (n = 1000), which was analyzed according to region of residence. While many respondents were unfamiliar with the VVA condition, most could relate their VVA symptoms to the menopause. The rate of diagnosis of VVA was twice as high in Central Italy as in the North-East...
February 21, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28267367/systematic-indirect-comparison-of-ospemifene-versus-local-estrogens-for-vulvar-and-vaginal-atrophy
#16
N Bruyniks, N Biglia, S Palacios, A O Mueck
In the absence of a direct head-to-head study, we performed an indirect historical comparison of ospemifene 60 mg (Senshio(®)) vs. local vaginal estrogens in moderate or severe vulvar and vaginal atrophy (VVA). A literature search was carried out of clinical efficacy/safety trials of local vaginal estrogens in VVA approved in Europe. For efficacy comparison, studies had to be placebo-controlled and of 12 weeks' duration. For safety comparison, studies had to be ≥40 weeks' duration. Efficacy endpoints were the difference between active and placebo in change from baseline to week 12 for symptoms, vaginal pH, and maturation value (MV)...
March 7, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28259230/vulvovaginal-issues-in-mature-women
#17
REVIEW
Mary L Marnach, Rochelle R Torgerson
Mature women often present with symptomatic vulvovaginal atrophy and vulvar dermatoses, causing noncoital pain, dyspareunia, and sexual changes. Diagnosis of these conditions can be challenging, and long-term management is required to decrease morbidity and enhance quality of life. Vaginal estrogen therapies remain safe and effective for treating symptomatic vulvovaginal atrophy. A vulvar biopsy is easy to perform and generally well tolerated when indicated for the diagnosis of lichen simplex chronicus, lichen sclerosus, and lichen planus...
March 2017: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/28243906/structural-reorganization-of-the-vaginal-mucosa-in-stress-urinary-incontinence-under-conditions-of-er-yag-laser-treatment
#18
G A Lapii, A Yu Yakovleva, A I Neimark
Structural characteristics of the vaginal mucosa in stress incontinence and its correction by IncontiLase technology were studied. Studies of vaginal biopsy specimens before the exposure showed degenerative and atrophic changes in the stratified squamous epithelium, disorganization of fibrillar structures of the intercellular matrix, and microcirculatory disorders. Studies after Er:YAG laser exposure showed signs of neocollagenogenesis and elastogenesis, foci of neoangiogenesis, reduction of epithelial degeneration and atrophy, and an increase of the fibroblast population...
February 2017: Bulletin of Experimental Biology and Medicine
https://www.readbyqxmd.com/read/28202320/the-women-s-empower-survey-identifying-women-s-perceptions-on-vulvar-and-vaginal-atrophy-and-its-treatment
#19
Sheryl A Kingsberg, Michael Krychman, Shelli Graham, Brian Bernick, Sebastian Mirkin
INTRODUCTION: Vulvar and vaginal atrophy (VVA) affects up to two thirds of postmenopausal women, but most symptomatic women do not receive prescription therapy. AIM: To evaluate postmenopausal women's perceptions of VVA and treatment options for symptoms in the Women's EMPOWER survey. METHODS: The Rose Research firm conducted an internet survey of female consumers provided by Lightspeed Global Market Insite. Women at least 45 years of age who reported symptoms of VVA and residing in the United States were recruited...
March 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28202319/the-women-s-empower-survey-women-s-knowledge-and-awareness-of-treatment-options-for-vulvar-and-vaginal-atrophy-remains-inadequate
#20
Michael Krychman, Shelli Graham, Brian Bernick, Sebastian Mirkin, Sheryl A Kingsberg
INTRODUCTION: Postmenopausal women's knowledge about vulvar and vaginal atrophy (VVA) and available treatment options has historically been inadequate. Recent direct-to-consumer marketing and educational efforts would have been expected to increase awareness and treatment options. AIM: To compare results of the Women's EMPOWER survey with other available VVA surveys to assess progress in women's understanding and approaches to treatment of VVA. METHODS: The Women's EMPOWER survey, an internet-based survey of US women with VVA symptoms, assessed women's awareness of VVA and their behaviors and attitudes associated with symptom treatment...
March 2017: Journal of Sexual Medicine
keyword
keyword
19676
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"